首站-论文投稿智能助手
典型文献
Design,synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors
文献摘要:
The abnormal activation of JAK2 kinase is closely related to the occurrence and progression of myelo-proliferative neoplasms(MPNs).At present,there is still an obvious unmet medical need for selective JAK2 inhibitors in clinic.In this paper,a class of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors was obtained by combining drug design,synthesis and structure-activity relationship studies based on the previously identified lead Crizotinib.Among them,21b exhibited high inhibitory activity against JAK2 with an IC50 of 9 nmol/L,moreover,it showed 276-and 184-fold selectivity over JAK1 and JAK3,respectively.Besides,21b had a significant antiproliferative activity against HEL cells,and also in-hibited the phosphorylation of JAK2 and its down-stream signaling pathway.These results indicated that 2-aminopyridine compound 21b had the potential to be developed as a selective JAK2 inhibitor for fur-ther study.
文献关键词:
作者姓名:
Dandan Liu;Huan Ge;Fangling Xu;Yufang Xu;Wenjun Liu;Honglin Li;Lili Zhu;Yanyan Diao;Zhenjiang Zhao
作者机构:
Shanghai Key Laboratory of New Drug Design,School of Pharmacy,East China University of Science and Technology,Shanghai 200237,China;Research and Development Department,Jiangzhong Pharmaceutical Co.,Ltd.,Nanchang 330096,China
引用格式:
[1]Dandan Liu;Huan Ge;Fangling Xu;Yufang Xu;Wenjun Liu;Honglin Li;Lili Zhu;Yanyan Diao;Zhenjiang Zhao-.Design,synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors)[J].中国化学快报(英文版),2022(06):2969-2974
A类:
aminopyridine,myelo,Crizotinib
B类:
Design,synthesis,SAR,study,derivatives,selective,JAK2,inhibitors,abnormal,activation,kinase,closely,related,occurrence,progression,neoplasms,MPNs,At,present,there,still,obvious,unmet,medical,need,clinic,In,this,paper,class,was,obtained,by,combining,drug,design,structure,activity,relationship,studies,previously,identified,lead,Among,them,21b,exhibited,high,inhibitory,against,IC50,nmol,moreover,showed,fold,selectivity,JAK1,JAK3,respectively,Besides,had,significant,antiproliferative,HEL,cells,also,phosphorylation,its,down,stream,signaling,pathway,These,results,indicated,that,compound,potential,be,developed,fur
AB值:
0.577534
相似文献
A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models
Ming Ji;Dongjie Wang;Songwen Lin;Chunyang Wang;Ling Li;Zhihui Zhang;Jing Jin;Deyu Wu;Yi Dong;Heng Xu;Duo Lu;Xiaoguang Chen-State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells
Qiufen Zhang;Yingyi Chen;Duan Ni;Zhimin Huang;Jiacheng Wei;Li Feng;Jun-Cheng Su;Yingqing Wei;Shaobo Ning;Xiuyan Yang;Mingzhu Zhao;Yuran Qiu;Kun Song;Zhengtian Yu;Jianrong Xu;Xinyi Li;Houwen Lin;Shaoyong Lu;Jian Zhang-State Key Laboratory of Oncogenes and Related Genes,Department of Pharmacy,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China;Medicinal Chemistry and Bioinformatics Center Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Nutshell Therapeutics,Shanghai 201203,China;Academy of Integrative Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;School of Pharmaceutical Sciences,Zhengzhou University,Zhengzhou 450001,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
Chengliang Sun;Yao Cheng;Xiaojia Liu;Gefei Wang;Wenjian Min;Xiao Wang;Kai Yuan;Yi Hou;Jiaxing Li;Haolin Zhang;Haojie Dong;Liping Wang;Chenguang Lou;Yanze Sun;Xinmiao Yu;Hongbin Deng;Yibei Xiao;Peng Yang-State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization,China Pharmaceutical University,Nanjing 210009,China;Department of Medicinal Chemistry,School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Department of Pharmacology,School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Beijing Institute of Clinical Pharmacy,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Department of Physics,Chemistry and Pharmacy,University of Southern Denmark,Campusvej 55,5230 Odense,Denmark;Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。